Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice

Pharmacology

Volumn 81, Issue 1, 2007, Pages 11-17

  Barone, Frank C ^a   Barton, Matthew E ^a   White, Ray F ^a   Legos, Jeffrey J ^a   Kikkawa, Hideo ^b   Shimamura, Midori ^b   Kuratani, Kazuyoshi ^b   Kinoshita, Mine ^b  

^a GLAXOSMITHKLINE   (United States)

^b Tsukuba Research Laboratories   (Japan)

Author keywords

cAMP regulation of gut contractility and absorption; Cold and restraint stress; Colonic motility; Colonic transit; Constipation; Diarrhea; Fecal pellet output; Irritable bowel syndrome; PDE enzyme activity; Stress induced defecation

Indexed keywords

LOPERAMIDE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; ROLIPRAM;

ANIMAL EXPERIMENT; ARTICLE; CAGE; COLD STRESS; COLON MOTILITY; CONTROLLED STUDY; DEFECATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENVIRONMENTAL TEMPERATURE; ENZYME INHIBITION; FECES; FECES ANALYSIS; IMMOBILIZATION STRESS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RODENT; ROOM TEMPERATURE; STRESS; WATER CONTENT; WEIGHT;

AMINOPYRIDINES; ANIMALS; ANTIDIARRHEALS; BENZAMIDES; COLD; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; DEFECATION; GASTROINTESTINAL MOTILITY; IRRITABLE BOWEL SYNDROME; LOPERAMIDE; MALE; MICE; MICE, INBRED C57BL; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RESTRAINT, PHYSICAL; ROLIPRAM; STRESS, PSYCHOLOGICAL;

EID: 36248932513     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107662     Document Type: Article

References (50)

1. Beavo JA, Hardman JG, Sutherland EW: Hydrolysis of cyclic guanosine and adenosine 3′,5′-monophosphates by rat and bovine tissues. J Biol Chem 1970;245:5649-5655.
2. Boswell-Smith V, Spina D, Page CP: Phosphodiesterase inhibitors. Br J Pharmacol 2006;147(suppl 1):S252-S257.
3. Beavo JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725-748.
4. Wallace DA, Johnston LA, Huston E, MacMaster D, Houslay TM, Cheung YF, Campbell L, Millen JE, Smith RA, Gall I, Knowles RG, Sullivan M, Houslay MD: Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene. Mol Pharmacol 2005;67:1920-1934.
5. Gupta R, Kumar G, Kumar RS: An update on cyclic nucleotide phosphodiesterase inhibitors: phosphodiesterases and drug selectivity. Methods Find Exp Clin Pharmacol 2005;27:101-118.
6. Houslay MD, Schafer P, Zhang KY: Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10:1503-1519.
7. Torphy TJ: Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998;157:351-370.
8. Abdel-Latif AA: Cross-talk between cyclic nucleotides and polyphosphoinositide hydrolysis, protein kinases, and contraction in smooth muscle. Exp Biol Med (Maywood) 2001;226:153-163.
9. Woodrum DA, Brophy CM: The paradox of smooth muscle physiology. Mol Cell Endocrinol 2001;177:135-143.
10. Keusch GT, Donowitz M: Pathophysiological mechanisms of diarrhoeal diseases: diverse aetiologies and common mechanisms. Scand J Gastroenterol Suppl 1983;84:33-43.
11. Barnette MS, Grous M, Torphy TJ, Ormsbee HS III: Activation of cyclic AMP-dependent protein kinase during canine lower esophageal sphincter relaxation. J Pharmacol Exp Ther 1990;252:1160-1166.
12. Barnette MS, Manning CD, Price WJ, Barone FC: Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle. J Pharmacol Exp Ther 1993;264:801-812.
13. Barone FC, Deegan JF, Price WJ, Fowler PJ, Fondacaro JD, Ormsbee HS III: Cold-restraint stress increases rat fecal pellet output and colonic transit. Am J Physiol 1990;258:G329-G337.
14. National Research Council: Guide for the Care and Use of Laboratory Animals. Washington, National Academy Press, 1996.
15. Tan-No K, Niijima F, Nakagawasai O, Sato T, Satoh S, Tadano T: Development of tolerance to the inhibitory effect of loperamide on gastrointestinal transit in mice. Eur J Pharm Sci 2003;20:357-363.
16. Russell J, Bass P, Goldberg LI, Schuster CR, Merz H: Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 1982;78:255-261.
17. Cann PA, Read NW, Holdsworth CD, Barends D: Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 1984;29:239-247.
18. Corbett CL, Thomas S, Read NW, Hobson N, Bergman I, Holdsworth CD: Electrochemical detector for breath hydrogen determination: measurement of small bowel transit time in normal subjects and patients with the irritable bowel syndrome. Gut 1981;22:836-840.
19. Heel RC, Brogden RN, Speight TM, Avery GS: Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs 1978;15:33-52.
20. Ruppin H: Review: loperamide - a potent antidiarrhoeal drug with actions along the alimentary tract. Aliment Pharmacol Ther 1987;1:179-190.
21. Menendez L, Lastra A, Meana A, Hidalgo A, Baamonde A: Analgesic effects of loperamide in bone cancer pain in mice. Pharmacol Biochem Behav 2005;81:114-121.
22. Sevostianova N, Danysz W, Bespalov AY: Analgesic effects of morphine and loperamide in the rat formalin test: interactions with NMDA receptor antagonists. Eur J Pharmacol 2005;525:83-90.
23. Hardcastle J, Hardcastle PT, Ayton B, Chapman J, MacNeil S: Calcium-calmodulin-dependent activation of adenylate cyclase in prostaglandin-induced electrically-monitored intestinal secretion in the rat. J Pharm Pharmacol 1992;44:93-96.
24. Sundaram U, Knickelbein RG, Dobbins JW: Mechanism of intestinal secretion: effect of cyclic AMP on rabbit ileal crypt and villus cells. Proc Natl Acad Sci USA 1991;88:6249-6253.
25. Izzo AA, Mascolo N, Capasso F: Effect of selective phosphodiesterase inhibitors on synaptic transmission in the guinea-pig ileum. Naunyn Schmiedebergs Arch Pharmacol 1998;357:677-681.
26. Izzo AA, Mascolo N, Costa M, Capasso F: Effect of papaverine on synaptic transmission in the guinea-pig ileum. Br J Pharmacol 1997;121:768-772.
27. Zafirov DH, Cooke HJ, Wood JD: Elevation of cAMP facilitates noradrenergic transmission in submucous neurons of guinea pig ileum. Am J Physiol 1993;264:G442-G446.
28. Calderaro V, Chiosi E, Greco R, Spina AM, Giovane A, Quagliuolo L, Servillo L, Balestrieri C, Illiano G: Role of calcium in chloride secretion mediated by cAMP pathway activation in rabbit distal colon mucosa. Am J Physiol 1993;264:G252-G260.
29. Beubler E, Badhri P: Comparison of the antisecretory effects of loperamide and loperamide oxide in the jejunum and the colon of rats in-vivo. J Pharm Pharmacol 1990;42:689-692.
30. Loeschke K, Schmid T, Farack UM: Inhibition by loperamide of mucus secretion in the rat colon in vivo. Eur J Pharmacol 1989;170:41-46.
31. 2-induced diarrhea in cecectomized rats. Arch Int Pharmacodyn Thér 1994;328:326-343.
32. Iona S, Cuomo M, Bushnik T, Naro F, Sette C, Hess M, Shelton ER, Conti M: Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain. Mol Pharmacol 1998;53:23-32.
33. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-290.
34. Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R: Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Pulm Pharmacol Ther 2006;19:343-352.
35. Karish SB, Gagnon JM: The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Ann Pharmacother 2006;40:1096-1104.
36. Krause W, Kuhne G: Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica 1988;18:561-571.
37. Reid P: Roflumilast Altana Pharma. Curr Opin Investig Drugs 2002;3:1165-1170.
38. Block F, Schmidt W, Nolden-Koch M, Schwarz M: Rolipram reduces excitotoxic neuronal damage. Neuroreport 2001;12:1507-1511.
39. 11C]rolipram-PET. Neuroimage 2005;26:1201-1210.
40. Randt CT, Judge ME, Bonnet KA, Quartermain D: Brain cyclic AMP and memory in mice. Pharmacol Biochem Behav 1982;17:677-680.
41. Zhu J, Mix E, Winblad B: The antidepressant and anti-inflammatory effects of rolipram in the central nervous system. CNS Drug Rev 2001;7:387-398.
42. Hatzelmann A, Schudt C: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-279.
43. Posserud I, Ersryd A, Simren M: Functional findings in irritable bowel syndrome. World J Gastroenterol 2006;12:2830-2838.
44. Guilera M, Balboa A, Mearin F: Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 2005;100:1174-1184.
45. Mearin F: Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders. Digestion 2006;73(suppl 1):28-37.
46. Schuster MM: Defining and diagnosing irritable bowel syndrome. Am J Manag Care 2001;7:S246-S251.
47. Whitehead WE, Crowell MD, Davidoff AL, Palsson OS, Schuster MM: Pain from rectal distension in women with irritable bowel syndrome: relationship to sexual abuse. Dig Dis Sci 1997;42:796-804.
48. Videla S, Vilaseca J, Medina C, Mourelle M, Guarner F, Salas A, Malagelada JR: Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. J Pharmacol Exp Ther 2006;316:940-945.
49. Bercik P, Verdu EF, Collins SM: Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 2005;34:235-245.
50. Quigley EM: Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? Chin J Dig Dis 2005;6:122-132.